Publication: Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting
Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting
Date
Date
Date
Citations
Stefan, N., Zimmermann, M., Simon, M., Zangemeister-Wittke, U., & Plückthun, A. (2014). Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting. Bioconjugate Chemistry, 25(12), 2144–2156. https://doi.org/10.1021/bc500468s
Abstract
Abstract
Abstract
Highly potent biotoxins like Pseudomonas exotoxin A (ETA) are attractive payloads for tumor targeting. However, despite replacement of the natural cell-binding domain of ETA by tumor-selective antibodies or alternative binding proteins like designed ankyrin repeat proteins (DARPins) the therapeutic window of such fusion toxins is still limited by target-independent cellular uptake, resulting in toxicity in normal tissues. Furthermore, the strong immunogenicity of the bacterial toxin precludes repeated administration in most patients.
Additional indexing
Creators (Authors)
- Stefan, Nikolas
- Zimmermann, Martina
- Simon, Manuel
- Zangemeister-Wittke, Uwe
- Plückthun, Andreas
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Citations
Stefan, N., Zimmermann, M., Simon, M., Zangemeister-Wittke, U., & Plückthun, A. (2014). Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting. Bioconjugate Chemistry, 25(12), 2144–2156. https://doi.org/10.1021/bc500468s
